325 related articles for article (PubMed ID: 26278511)
21. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
Haberer JE
Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
[TBL] [Abstract][Full Text] [Related]
22. Animal models of antiretroviral prophylaxis for HIV prevention.
García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2012 Nov; 7(6):505-13. PubMed ID: 22964889
[TBL] [Abstract][Full Text] [Related]
23. Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for?
Hankins CA
Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):167-70. PubMed ID: 24552641
[TBL] [Abstract][Full Text] [Related]
24. Preparing for PrEP.
Lacor P
Eur J Contracept Reprod Health Care; 2012 Dec; 17(6):482-6. PubMed ID: 23113873
[TBL] [Abstract][Full Text] [Related]
25. Configuring the users of new HIV-prevention technologies: the case of HIV pre-exposure prophylaxis.
Holt M
Cult Health Sex; 2015; 17(4):428-39. PubMed ID: 25270549
[TBL] [Abstract][Full Text] [Related]
26. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
[TBL] [Abstract][Full Text] [Related]
27. Role and modulation of drug transporters in HIV-1 therapy.
Alam C; Whyte-Allman SK; Omeragic A; Bendayan R
Adv Drug Deliv Rev; 2016 Aug; 103():121-143. PubMed ID: 27181050
[TBL] [Abstract][Full Text] [Related]
28. Translational Models to Predict Target Concentrations for Pre-Exposure Prophylaxis in Women.
Lantz AM; Nicol MR
AIDS Res Hum Retroviruses; 2022 Dec; 38(12):909-923. PubMed ID: 36097755
[TBL] [Abstract][Full Text] [Related]
29. Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis.
Gunawardana M; Mullen M; Moss JA; Pyles RB; Nusbaum RJ; Patel J; Vincent KL; Wang C; Guo C; Yuan YC; Warden CD; Baum MM
PLoS One; 2013; 8(10):e77340. PubMed ID: 24143220
[TBL] [Abstract][Full Text] [Related]
30. Beyond the ITC White Paper: emerging sciences in drug transporters and opportunities for drug development.
Lai Y; Hsiao P
Curr Pharm Des; 2014; 20(10):1577-94. PubMed ID: 23789952
[TBL] [Abstract][Full Text] [Related]
31. Antiretroviral pharmacology in mucosal tissues.
Thompson CG; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S240-7. PubMed ID: 23764642
[TBL] [Abstract][Full Text] [Related]
32. One step closer to ultra-long-acting PREP?
Harper KN
AIDS; 2019 Mar; 33(3):N2. PubMed ID: 30585839
[No Abstract] [Full Text] [Related]
33. Comprehensive Study of Antiretroviral Drug Permeability at the Cervicovaginal Mucosa
Carserides C; Smith K; Zinicola M; Kumar A; Swedrowska M; Scala C; Cameron G; Riches Z; Iannelli F; Pozzi G; Hold GL; Forbes B; Kelly C; Hijazi K
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145684
[TBL] [Abstract][Full Text] [Related]
34. Transporters and drug discovery: why, when, and how.
Kim RB
Mol Pharm; 2006; 3(1):26-32. PubMed ID: 16686366
[TBL] [Abstract][Full Text] [Related]
35. Glutamine transporters as pharmacological targets: From function to drug design.
Scalise M; Pochini L; Galluccio M; Console L; Indiveri C
Asian J Pharm Sci; 2020 Mar; 15(2):207-219. PubMed ID: 32373200
[TBL] [Abstract][Full Text] [Related]
36. Role of transporters in ocular drug delivery system.
Mitra AK
Pharm Res; 2009 May; 26(5):1192-6. PubMed ID: 19291373
[No Abstract] [Full Text] [Related]
37. Special topic: Emerging role of transporters in drug interaction and delivery.
Kou L; He Z; Sun J
Asian J Pharm Sci; 2020 Mar; 15(2):129-130. PubMed ID: 32373194
[No Abstract] [Full Text] [Related]
38. ABCG2 polymorphisms and susceptibility to ARV-associated hepatotoxicity.
Singh H; Dhotre K; Shyamveer ; Choudhari R; Verma A; Mahajan SD; Ali N
Mol Genet Genomic Med; 2024 Mar; 12(3):e2362. PubMed ID: 38451012
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV.
Zondo NM; Sobia P; Sivro A; Ngcapu S; Ramsuran V; Archary D
Front Genet; 2022; 13():940661. PubMed ID: 36246609
[TBL] [Abstract][Full Text] [Related]
40. In vitro and ex vivo models for evaluating vaginal drug delivery systems.
Shapiro RL; DeLong K; Zulfiqar F; Carter D; Better M; Ensign LM
Adv Drug Deliv Rev; 2022 Dec; 191():114543. PubMed ID: 36208729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
